Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab Maintenance in Relapsed CLL (PROLONG)
NCT01039376Phase 3Terminated
- Sponsor
- Novartis
- Start
- May 2010
- Primary completion
- Feb 2017
- Modality
- Monoclonal Antibodies
- Countries
- 25
01
Overview
A Phase 3 trial of ofatumumab in chronic lymphocytic leukemia (CLL), sponsored by Novartis. Started May 2010; status: terminated.
02
Drugs
ofatumumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT01039376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01039376.